| Literature DB >> 25877150 |
Emery Smith1, Peter Chase1, Colleen M Niswender2, Thomas J Utley2, Douglas J Sheffler3, Meredith J Noetzel2, Atin Lamsal2, Michael R Wood2, P Jeffrey Conn2, Craig W Lindsley2, Franck Madoux1, Mary Acosta1, Louis Scampavia1, Timothy Spicer4, Peter Hodder5.
Abstract
Muscarinic acetylcholine receptors (mAChRs) have long been viewed as viable targets for novel therapeutic agents for the treatment of Alzheimer's disease and other disorders involving impaired cognitive function. In an attempt to identify orthosteric and allosteric modulators of the muscarinic acetylcholine receptor M(4) (M(4)), we developed a homogenous, multiparametric, 1536-well assay to measure M(4) receptor agonism, positive allosteric modulation (PAM), and antagonism in a single well. This assay yielded a Z' of 0.85 ± 0.05 in the agonist, 0.72 ± 0.07 in PAM, and 0.80 ± 0.06 in the antagonist mode. Parallel screening of the M(1) and M(5) subtypes using the same multiparametric assay format revealed chemotypes that demonstrate selectivity and/or promiscuity between assays and modalities. This identified 503 M(4) selective primary agonists, 1450 PAMs, and 2389 antagonist hits. Concentration-response analysis identified 25 selective agonists, 4 PAMs, and 41 antagonists. This demonstrates the advantages of this approach to rapidly identify selective receptor modulators while efficiently removing assay artifacts and undesirable compounds.Entities:
Keywords: GPCR; muscarinic; parallel screening; positive allosteric modulators
Mesh:
Substances:
Year: 2015 PMID: 25877150 PMCID: PMC4659430 DOI: 10.1177/1087057115581770
Source DB: PubMed Journal: J Biomol Screen ISSN: 1087-0571